Ladarixin, a dual inhibitor of IL-8 receptors CXCR1 and CXCR2 with an optimal pharmacokinetic profile [25] that has completed phase I studies and already entered phase II/III trials, was previously used in in vivo murine model to achieve the pharmacologic inhibition of the CXCL1–CXCR1/2 axis [24], obtaining promising results in maintaining residual B-cells and making the potential to significantly adjust the approach for managing human type 1 diabetes. The gene discussed is CXCR1; the disease is type 1 diabetes mellitus.